All Pharma articles – Page 28
-
NewsQIPP lead: drugs bill will increase
Providers and commissioners need to focus on making sure they achieve value for money on drugs rather than cutting overall spend, the government’s pharmaceutical spending efficiency expert has told HSJ.
-
NewsReport: NHS slipping on Innovation, Health and Wealth targets
There has been a “disappointing” lack of local engagement with the government’s plan to improve the spread of innovation in the NHS, new research has concluded.
-
NewsMedicines body review announced
Concerns about the inconsistent availability of some medicines in Scotland has prompted a review of the decision-making process at the NHS’s drugs approval body.
-
SupplementsDrug action - an HSJ supplement on primary care
From recruitment challenges to a greater role for pharmacies, our supplement probes the latest developments in primary care
-
HSJ KnowledgeWhy pharmacies must think big
If pharmacists fail to grasp the opportunities before them, someone else will
-
HSJ KnowledgeDispense with the old way of doing things
Lack of transparency in the medicines supply chain is of concern to many observers
-
NewsQIPP medicines management schemes get green light
QIPP plans to reduce spending on medicines are making better progress than other major workstreams.
-
NewsGovernment rejects BMA's rationing warning
The government has rejected a warning by the new leader of Britain’s doctors that the health of NHS patients was being put at risk because they were being denied access to operations and drugs.
-
NewsCall to maintain Cancer Drugs Fund
Tens of thousands of cancer sufferers could be denied life-extending drugs unless the government finds a way to continue funding treatment for patients, a charity has warned.
-
HSJ KnowledgeStepping good practice up a gear
HIECs are invaluable in delivering improvement at scale and pace
-
HSJ Local
Commissioners report Lucentis pressure from Newcastle FT
FINANCE: North Tyneside PCT, Northumberland CT and Newcastle PCT are facing overspending risks in relation to Newcastle upon Tyne Hospitals Foundation Trust, largely attributable to use of Lucentis (ranibizumab injection).
-
NewsNicholson orders trusts to offer approved drugs
All NHS organisations have been ordered to publish details of which drugs they will routinely fund in a bid to make sure patients get medicines they are legally entitled to.
-
HSJ KnowledgePatients 'should take trusts to court' over drug access
‘Numerous trusts are acting unlawfully… denying patients an innovative and cost-effective treatment,’ writes NICE chair Sir Michael Rawlins in a recent HSJ article. Read the article, listen to the BBC’s follow-up and share your views.
-
NewsGames drug testing labs to become research centre
A £10m scientific research centre is to be based on the site of Olympic drug testing laboratories, David Cameron has announced.
-
NewsSHIP cluster U-turns on Lucentis policy after price is slashed
A primary care trust cluster under the threat of legal action for recommending the use of an unlicensed drug has revoked the policy after the pharmaceutical company cut the price of the medicine.
-
HSJ Local
New prescription pager system for Frimley Park
COMMERCIAL: Frimley Park Foundation Trust has purchased a pager system to help improve patient satisfaction levels.
-
HSJ PartnersCan outsourcing outpatient dispensing play a role in delivering QIPP?
HSJ and The Co-operative Pharmacy want your opinion on outsourcing outpatient pharmacy dispensing. Take part in our questionnaire and have your say
-
NewsExclusive: fear over Olympic drugs overseas sell-on
Some pharmacies in London may request additional drug supplies during the Olympics only to sell them off overseas for profit, it has been claimed.
-
NewsManagement of AF 'needs revising'
A potentially life-threatening heart rhythm disorder is not being properly managed in the UK, according to a new report.
-
NewsSpend on new drugs expected to drop
The drugs industry expects the NHS to cut its real terms spend on new medicines over the next three years - but it is warning that the slow adoption of new drugs could create avoidable costs.